Supplementary Figure 3 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
crossref(2023)
摘要
Progression free survival and overall survival curves.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要